Cavo M, Schjesvold F, Dimopoulos M, Delforge M, Escalante F, Kleinman D, Lee HC, Vij R, Greil R, Melchardt T, Antonioli E, Lysen A, Camadoo-O'Byrne L, Bitetti J, D'Estrube T, Fry M, Byrne J, Vossen CY, Sapra S, Benson VS, Mouro J, Hultcrantz M(2026) Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe Haematologica(in press) DOI 10.3324/haematol.2025.289034, PubMed 41568469
Acs K, Miettinen JJ, Sergeev P, Heckel T, Diao Y, Witt-Mulder K, Thureson M, Bischler T, Huppunen ME, Suvela M, Obermüller J, Munawar U, Slipicevic A, Bargou RC, Lehmann F, Gelius SS, Norin S, Schjesvold F, Sonneveld P, Stühmer T, Heckman CA(2025) Efficacy of melflufen in multiple myeloma with mutated or deleted TP53 Exp Hematol Oncol, 14(1), 138 DOI 10.1186/s40164-025-00729-1, PubMed 41437395
Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F(2025) Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma Blood Cancer J, 15(1), 214 DOI 10.1038/s41408-025-01407-5, PubMed 41429779
